Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Abstract

Neoadjuvant PD-1 Blockade in Lung Cancer In a pilot study, two doses of neoadjuvant nivolumab administered to patients with resectable lung cancer resulted in a major pathological response in 45% and amplified T-cell clones specific for tumor antigens.

Publication
New England Journal of Medicine

Related